One study showed that liraglutide, a GLP-1 receptor agonist approved for human T2D and obesity, improved glycemic control during hyperglycemia in healthy cats by increasing insulin concentrations and decreasing glucagon concentrations. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.